Skip to content use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time, details of which can be found in our cookie policy. However please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

PHARMBIOTEST supported drug manufacturers and did not discontinue clinical trials at the peak of the pandemics

21 April 2021


Clinical and Diagnostic Center Pharmbiotest managed not to suspend the process of conducting clinical trials regardless the quarantine regime in Ukraine imposed because of corona virus SARS-CoV-2 last year.

At the very beginning of the pandemics Pharmbiotest’s laboratory started conducting PCR diagnostics among the company’s employees, as well as all health volunteers – participants of trials.

As Kateryna Kovalyova, Deputy Director for Research of CDC Pharmbiotest, said, such mandatory diagnostics had been carried out at the company’s initiative. PCR tests are performed at the stage of screening before every hospitalization within the study periods, as well as at the end of the study. Biomaterial is sampled in the special isolated boxes, which get disinfected before and after each patient to prevent any possible human infection at the time of sampling.

“Mandatory PCR diagnostics of our employees and healthy volunteers of clinical trials before each hospitalization had been implemented at our own initiative before recommendations of the State Expert Center were published. This way we did not have to suspend our studies for a long period of time, and returned to normal operation within 2 months of the active phase of the pandemics. Thus, we conducted 2 trials the last year, and within the first months of this year we already completed one trial and started another one, which means that the process of conducting clinical trials follows our schedule without fail”, Kateryna Kovalyova explained.

It is noteworthy that Clinical and Diagnostic Center Pharmbiotest is one of the leaders in the field of clinical studies on pharmacokinetics and bioequivalence of drugs in Ukraine. Uninterrupted operation of our company ensures the possibility of registration of quality generic drugs of domestic production and bringing them to Ukrainian market. It was made possible due to implementation of procedures ensuring high level of safety for healthy volunteers and the personnel of the Center.

Scroll To Top